{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T21:37:05Z","timestamp":1781905025168,"version":"3.54.5"},"reference-count":44,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["bjanaesthesia.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["British Journal of Anaesthesia"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.bja.2025.03.006","type":"journal-article","created":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T16:28:37Z","timestamp":1744820917000},"page":"1591-1596","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Developing novel drugs to reverse neuromuscular block: do we need them?"],"prefix":"10.1016","volume":"134","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1993-6410","authenticated-orcid":false,"given":"Jennifer M.","family":"Hunter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manfred","family":"Blobner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bja.2025.03.006_bib1","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.bjae.2020.03.008","article-title":"Reversal of neuromuscular block","volume":"20","author":"Hunter","year":"2020","journal-title":"BJA Educ"},{"key":"10.1016\/j.bja.2025.03.006_bib2","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/00000542-200201000-00013","article-title":"Efficacy of tactile-guided reversal from cisatracurium-induced neuromuscular block","volume":"96","author":"Kirkegaard","year":"2002","journal-title":"Anesthesiology"},{"key":"10.1016\/j.bja.2025.03.006_bib3","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/bja\/aev437","article-title":"Sugammadex and neostigmine dose-finding study for reversal of residual neuromuscular block at a train-of-four ratio of 0.2 (SUNDRO20)","volume":"116","author":"Kaufhold","year":"2016","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.bja.2025.03.006_bib4","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jclinane.2017.06.006","article-title":"Sugammadex efficacy for reversal of rocuronium- and vecuronium-induced neuromuscular blockade: a pooled analysis of 26 studies","volume":"41","author":"Herring","year":"2017","journal-title":"J\u00a0Clin Anesth"},{"key":"10.1016\/j.bja.2025.03.006_bib5","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1093\/bja\/aen037","article-title":"Reversal of rocuronium-induced neuromuscular block with sugammadex is faster than reversal of cisatracurium-induced block with neostigmine","volume":"100","author":"Flockton","year":"2008","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.bja.2025.03.006_bib6","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.bja.2018.04.014","article-title":"Anaesthesia, surgery, and life-threatening allergic reactions: epidemiology and clinical features of perioperative anaphylaxis in the 6th National Audit Project (NAP6)","volume":"121","author":"Harper","year":"2018","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.bja.2025.03.006_bib7","series-title":"Adverse events reporting system (FAERS) public dashboard","year":"2021"},{"key":"10.1016\/j.bja.2025.03.006_bib8","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.bja.2018.03.003","article-title":"Sugammadex-induced bradycardia and asystole: how great is the risk?","volume":"121","author":"Hunter","year":"2018","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.bja.2025.03.006_bib9","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1097\/00000542-200309000-00018","article-title":"Reversal of neuromuscular blockade and simultaneous increase in plasma rocuronium concentration after the intravenous infusion of the novel reversal agent Org 25969","volume":"99","author":"Epemolu","year":"2003","journal-title":"Anesthesiology"},{"key":"10.1016\/j.bja.2025.03.006_bib10","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1093\/bja\/aen216","article-title":"Multicentre, parallel-group, comparative trial evaluating the efficacy and safety of sugammadex in patients with end-stage renal failure or normal renal function","volume":"101","author":"Staals","year":"2008","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.bja.2025.03.006_bib11","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1097\/EJA.0000000000000312","article-title":"Efficacy and safety of sugammadex in the reversal of deep neuromuscular blockade induced by rocuronium in patients with end-stage renal disease: a comparative prospective clinical trial","volume":"32","author":"de Souza","year":"2015","journal-title":"Eur J Anaesth"},{"key":"10.1016\/j.bja.2025.03.006_bib12","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1213\/ANE.0000000000006807","article-title":"Sugammadex versus neostigmine for reversal of neuromuscular blockade in patients with severe renal impairment: a randomized, double-blinded study","volume":"138","author":"Oh","year":"2024","journal-title":"Anesth Analg"},{"key":"10.1016\/j.bja.2025.03.006_bib13","article-title":"The arousal effect of sugammadex reversal of neuromuscular blockade differs with anesthetic depth in propofol-remifentanil anesthesia: a randomized controlled trial","volume":"13","author":"Kim","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.bja.2025.03.006_bib14","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1093\/bja\/aex116","article-title":"Deep neuromuscular block to optimize surgical space conditions during laparoscopic surgery: a systematic review and meta-analysis","volume":"118","author":"Bruintjes","year":"2017","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.bja.2025.03.006_bib15","series-title":"Bridion (sugammadex). an overview of Bridion and why it is authorised in the EU","year":"2025"},{"key":"10.1016\/j.bja.2025.03.006_bib16","series-title":"Supplement approval. Fulfillment of postmarketing requirement","year":"2024"},{"key":"10.1016\/j.bja.2025.03.006_bib17","article-title":"Costs of drug development and research and development intensity in the US, 2000-2018","volume":"28","author":"Sertkava","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.bja.2025.03.006_bib18","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/ALN.0b013e3182910213","article-title":"Calabadion: a new agent to reverse the effects of benzylisoquinoline and steroidal neuromuscular-blocking agents","volume":"119","author":"Hoffmann","year":"2013","journal-title":"Anesthesiology"},{"key":"10.1016\/j.bja.2025.03.006_bib19","doi-asserted-by":"crossref","first-page":"13313","DOI":"10.1002\/anie.202005902","article-title":"Pillar[n]MaxQ: a new high affinity host family for sequestration in water","volume":"59","author":"Xue","year":"2020","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.bja.2025.03.006_bib20","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/s12871-021-01424-4","article-title":"Carboxymethyl-gamma-cyclodextrin, a novel selective relaxant binding agent for the reversal of neuromuscular block induced by aminosteroid neuromuscular blockers: an ex\u00a0vivo laboratory study","volume":"21","author":"Fabian","year":"2021","journal-title":"BMC Anesthesiol"},{"key":"10.1016\/j.bja.2025.03.006_bib21","series-title":"United States patent. 6-mercapto-cyclodextrin derivatives: reversal agents for drug-induced neuromuscular block","author":"Zhang","year":"2006"},{"key":"10.1016\/j.bja.2025.03.006_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2019.105134","article-title":"Safety, tolerability, and pharmacokinetics of adamgammadex sodium, a novel agent to reverse the action of rocuronium and vecuronium, in healthy volunteers","volume":"141","author":"Jiang","year":"2020","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.bja.2025.03.006_bib23","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.bja.2023.10.022","article-title":"Phase III clinical trial comparing the efficacy and safety of adamgammadex with sugammadex for reversal of rocuronium-induced neuromuscular block","volume":"132","author":"Zhang","year":"2024","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.bja.2025.03.006_bib24","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.1111\/bcp.15320","article-title":"Adamgammadex in patients to reverse a moderate rocuronium-induced neuromuscular block","volume":"88","author":"Jiang","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.bja.2025.03.006_bib25","doi-asserted-by":"crossref","first-page":"11358","DOI":"10.1002\/anie.201206031","article-title":"Acyclic cucurbit[n]uril-type molecular containers bind neuromuscular blocking agents in\u00a0vitro and reverse neuromuscular block in\u00a0vivo","volume":"51","author":"Ma","year":"2012","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.bja.2025.03.006_bib26","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/nchem.1326","article-title":"Acyclic cucurbit[n]uril molecular containers enhance the solubility and bioactivity of poorly soluble pharmaceuticals","volume":"4","author":"Ma","year":"2012","journal-title":"Nat Chem"},{"key":"10.1016\/j.bja.2025.03.006_bib27","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1097\/ALN.0000000000000868","article-title":"Comparative effectiveness of calabadion and sugammadex to reverse non-depolarizing neuromuscular-blocking agents","volume":"123","author":"Haerter","year":"2015","journal-title":"Anesthesiology"},{"key":"10.1016\/j.bja.2025.03.006_bib28","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.chempr.2022.11.019","article-title":"Pillar[6]MaxQ: a potent supramolecular host for in\u00a0vivo sequestration of methamphetamine and fentanyl","volume":"9","author":"Brockett","year":"2023","journal-title":"Chem"},{"key":"10.1016\/j.bja.2025.03.006_bib29","doi-asserted-by":"crossref","first-page":"4350","DOI":"10.1039\/D4CC00772G","article-title":"Pillar[6]MaxQ functions as an in\u00a0vivo sequestrant for rocuronium and vecuronium","volume":"60","author":"Zhang","year":"2024","journal-title":"Chem Commun (Camb)"},{"key":"10.1016\/j.bja.2025.03.006_bib30","doi-asserted-by":"crossref","DOI":"10.1213\/ANE.0000000000007336","article-title":"Pillar[6]MaxQ and sugammadex enhance recovery from rocuronium- and vecuronium-mediated neuromuscular blockade with similar effects in isoflurane-anesthetized rats","author":"Cotten","year":"2025","journal-title":"Anesth Analg Adv Access"},{"key":"10.1016\/j.bja.2025.03.006_bib31","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/BF03256937","article-title":"Assessment of the potential for displacement interactions with sugammadex: a pharmacokinetic-pharmacodynamic modelling approach","volume":"31","author":"Zwiers","year":"2011","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.bja.2025.03.006_bib32","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1097\/ALN.0000000000000424","article-title":"Effect of reversal of neuromuscular blockade with sugammadex versus usual care on bleeding risk in a randomized study of surgical patients","volume":"121","author":"Rahe-Meyer","year":"2014","journal-title":"Anesthesiology"},{"key":"10.1016\/j.bja.2025.03.006_bib33","doi-asserted-by":"crossref","first-page":"e412","DOI":"10.1016\/j.bja.2022.11.017","article-title":"Contraceptive failure and sugammadex administration: a single centre survey and audit of professional knowledge and practice","volume":"130","author":"Passi","year":"2023","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.bja.2025.03.006_bib34","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/ALN.0000000000001199","article-title":"A\u00a0novel strategy to reverse general anesthesia by scavenging with the acyclic cucurbit[n]uril-type molecular container calabadion 2","volume":"125","author":"Diaz-Gil","year":"2016","journal-title":"Anesthesiology"},{"key":"10.1016\/j.bja.2025.03.006_bib35","doi-asserted-by":"crossref","first-page":"e140","DOI":"10.1016\/j.bja.2020.02.019","article-title":"Calabadion 1 selectively reverses respiratory and central nervous system effects of fentanyl in a rat model","volume":"125","author":"Thevathasan","year":"2020","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.bja.2025.03.006_bib36","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.bja.2019.10.016","article-title":"Comparison of incidence of anaphylaxis between sugammadex and neostigmine: a retrospective multicentre observational study","volume":"124","author":"Orihara","year":"2020","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.bja.2025.03.006_bib37","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.bja.2024.07.042","article-title":"Sugammadex hypersensitivity: a multicentre retrospective analysis of a large Australian cohort","volume":"134","author":"Crimmins","year":"2025","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.bja.2025.03.006_bib38","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.bja.2018.05.057","article-title":"Sugammadex hypersensitivity and underlying mechanisms: a randomised study of healthy non-anaesthetised volunteers","volume":"121","author":"de Kam","year":"2018","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.bja.2025.03.006_bib39","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.bja.2020.01.003","article-title":"Anaphylaxis to sugammadex: should we be concerned by the Japanese experience?","volume":"124","author":"Savic","year":"2020","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.bja.2025.03.006_bib40","first-page":"515e26","article-title":"Screened adamgammadex for reversing rocuronium-induced neuromuscular blockade with greater safety","volume":"32","author":"Qi","year":"2018","journal-title":"Chin J Pharmacol Toxicol"},{"key":"10.1016\/j.bja.2025.03.006_bib41","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.bja.2023.11.006","article-title":"Is adamgammadex the brother of sugammadex or the next generation of reversal agent?","volume":"132","author":"Hunter","year":"2024","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.bja.2025.03.006_bib42","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1186\/s12871-021-01477-5","article-title":"A\u00a0randomized trial evaluating the safety profile of sugammadex in high surgical risk ASA physical class 3 or 4 participants","volume":"21","author":"Herring","year":"2021","journal-title":"BMC Anesthesiol"},{"key":"10.1016\/j.bja.2025.03.006_bib43","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1021\/jm011107f","article-title":"Cyclodextrin-derived host molecules as reversal agents for the neuromuscular blocker rocuronium bromide: synthesis and structure-activity relationships","volume":"45","author":"Adam","year":"2002","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.bja.2025.03.006_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.bja.2025.04.031","article-title":"Efficacy and safety of adamgammadex for reversing rocuronium-induced deep neuromuscular blockade: a multicentre, randomised, double-blind, positive-controlled phase III study","author":"Zhao","year":"2025","journal-title":"Br J Anaesth"}],"container-title":["British Journal of Anaesthesia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007091225001606?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007091225001606?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:38:31Z","timestamp":1780274311000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007091225001606"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S0007091225001606"],"URL":"https:\/\/doi.org\/10.1016\/j.bja.2025.03.006","relation":{},"ISSN":["0007-0912"],"issn-type":[{"value":"0007-0912","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Developing novel drugs to reverse neuromuscular block: do we need them?","name":"articletitle","label":"Article Title"},{"value":"British Journal of Anaesthesia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bja.2025.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 British Journal of Anaesthesia. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}